ObjectiveTo investigate the correlation between serum salusin-β, soluble neurite outgrowth inhibitor-B(sNogo-B) with disease progression and cognitive impairment(CI) in Parkinson's disease(PD) patients.MethodsFrom January 2021 to December 2023, 124 PD patients in the Department of Neurology, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University were selected as PD group, and 85 healthy people in the same period were selected as healthy control group. PD patients were divided into early subgroup(n=56) and middle and late subgroup(n=68) according to their disease progression, and then divided into PD-NCI subgroup(n=52) and PD-CI subgroup(n=72) according to whether PD patients were accompanied by CI or not. Serum levels of salusin-β and sNogo-B were detected by enzyme-linked immunosorbent assay. Hoehn-Yahr staging was used to stage the disease progression of PD patients; The Montreal Cognitive Assessment Scale(MoCA) was used to evaluate the cognitive function of PD patients. Spearman correlation analysis was used to analyze the correlation between serum salusin-β and sNogo-B levels and disease progression and CI in PD patients. Diagnostic value of analyzing serum salusin-β and sNogo-B levels by ROC curve in PD patients with disease progression and accompanying CI.ResultsThe serum levels of salusin-β and sNogo-B in PD group were lower than those in healthy control group(t/P=8.694/<0.001, 7.923/<0.001). The serum levels of salusin-β and sNogo-B in the middle and late subgroup were lower than those in the early subgroup(t/P=6.709/<0.001, 7.059/<0.001). Serum salusin-β and sNogo-B levels in PD-CI subgroup were lower than those in PD-NCI subgroup(t/P=6.062/<0.001,8.767/<0.001). The serum levels of salusin-β and sNogo-B in PD patients were negatively correlated with the progression of the disease and accompanying CI(r=-0.408,-0.412,-0.403,-0.406, allP<0.001). The AUC of serum salusin-β, sNogo-B and their combined diagnosis of PD patients with CI were 0.796, 0.820 and 0.918, respectively. The AUC of serum salusin-β and sNogo-B was higher than that predicted by serum Salusin-β and Snogo-B alone(Z= 3.702, 3.044,P< 0.001, 0.002).ConclusionThe serum levels of salusin-β and sNogo-B in PD patients are low, and further decrease with the disease progression and accompanying CI. Compared with single diagnosis, the combined diagnosis of salusin-β and snogo-B has higher value, which provides theoretical support for clinical diagnosis.

ObjectiveTo investigate the effects of linezolid combined with meropenem on blood gas indicators and serum annexin A1(ANXA1) level in patients with severe pneumonia(SP).MethodsA total of 100 patients with SP admitted to the Emergency Medicine Department of the 910th Hospital of the Joint Logistic Support Force of the Chinese People's Liberation Army from June 2021 to December 2023 were selected as the research objects. the patients were randomly separated into a meropenem group(50 cases) and a combination group(50 cases). The meropenem group was treated with meropenem, while the Combination group was treated with meropenem combined with linezolid. Both groups were treated continuously for 2 weeks. The clinical efficacy, clinical indicators, ANXA1, blood gas indicators, lung function indicators, serum inflammatory factors, and adverse reactions of the two groups after treatment were observed.ResultsAfter treatment, the total clinical effective rate of the Combination group was 96.00%(48/50), while the total effective rate of the meropenem group was 74.00%(37/50), the Combination group was obviously higher than the meropenem group(Z/P=9.490/0.002). The fever disappearance time, sputum disappearance time, sputum bacterial conversion time, hospitalization time in the Combination group were obviously reduced compared to the meropenem group(t/P=15.915/<0.001, 6.864/<0.001, 8.283/<0.001, 8.336/<0.001). The levels of arterial oxygen partial pressure(PaO2), arterial oxygen saturation(SaO2), and transforming growth factor-β(TGF-β) were obviously increased in both groups compared to before treatment, while the Combination group was obviously higher than the meropenem group(t/P=11.628/<0.001, 3.365/<0.001, 11.679/<0.001). The lung function indicators[maximum mid expiratory flow(MMEF), peak expiratory flow(PEF), and forced vital capacity(FVC)]of two groups were obviously improved compared to before treatment, and the Combination group was obviously higher than the meropenem group(t/P=5.636/<0.001, 4.162/<0.001, 2.851/0.005). The interleukin-1β(IL-1β), procalcitonin(PCT), and C-reactive protein(CRP), Annexin A1 were obviously reduced compared to before treatment, and the Combination group was obviously lower than the meropenem group(t/P=3.902/<0.001, 4.576/<0.001, 20.185/<0.001, 21.947/<0.001,6.907/<0.001). The total incidence of adverse reactions(rash, dizziness, nausea, diarrhea) in the Combination group was 6.00%, while in the meropenem group it was 12.00%, there was no obvious difference in adverse reactions between the two groups(P>0.05).ConclusionThe combination of linezolid and meropenem in treating SP can improve the clinical efficacy of patients, reduce inflammatory reactions and ANXA1 levels, improve clinical symptoms, blood gas indicators, and lung function indicators, and has high safety.

ObjectiveTo analyze the correlation between serum tumor necrosis factor receptor associated factor 6(TRAF6), complement C1q tumor necrosis factor related protein 9(CTRP9) levels and fetal growth restriction(FGR) in pregnant women with hypertension disorders in pregnancy(HDP).MethodsFrom February 2021 to February 2024, 110 pregnant women with HDP treated in Department of Obstetrics and Gynecology, Northwest Women and Children's Hospital were selected. According to fetal growth, they were assigned into two groups: the observation Group(39 cases) and the control group(71 cases). Enzyme linked immunosorbent assay(ELISA) was used to detect serum levels of TRAF6 and CTRP9. Measure the fetal biparietal diameter, femoral length, abdominal circumference, head circumference and BMI value after birth. All basic information of the research subjects was statistically analyzed. Spearman method was used for correlation analysis. The risk factors affecting FGR in pregnant women with HDP were analyzed using a multiple logistic regression model. ROC was used to analyze the predictive value of serum TRAF6 and CTRP9 for FGR in pregnant women with HDP.ResultsCompared with the control group, pregnant women in the observation Group had higher serum TRAF6, lower serum CTRP9(t/P=5.962/<0.001, 5.848/<0.001), and higher proportions of vitamin D deficiency, abnormal umbilical blood flow, and placental abnormalities(χ2/P=8.506/0.004, 41.412/<0.001, 31.174/<0.001). Besides, lower indexes biparietal diameter, femur length, and abdominal circumference, head circumference and BMI values after birth in the observation Group(t/P=8.947/<0.001, 12.560/<0.001, 5.118/<0.001, 7.307/<0.001, 8.930/<0.001). The serum TRAF6 was positively correlated with vitamin D deficiency, abnormal umbilical blood flow, placental abnormalities, and FGR occurrence(r/P=0.492/<0.001, 0.423/<0.001, 0.568/<0.001, 0.422/<0.001; while the serum CTRP9 was negatively correlated with vitamin D deficiency, abnormal umbilical blood flow, placental abnormalities, and FGR occurrence(r/P=-0.513/<0.001,-0.416/<0.001,-0.594/<0.001,-0.419/<0.001). High serum TRAF6 is an influencing factor for FGR in pregnant women with HDP, and high CTRP9 is a protective factor for FGR in pregnant women with HDP [OR(95%CI)=1.995(1.166-3.413), 0.354(0.190-0.658)], The AUC values of serum TRAF6, CTRP9 levels and their combination for predicting FGR in pregnant women with HDP were 0.858, 0.826 and 0.938, respectively. The combination of the two was superior to the single prediction efficiency(Z=2.820, 3.510,P=0.005,P<0.001).ConclusionThe levels of TRAF6 and CTRP9 are elevated in the serum of HDP pregnant women with FGR. Both are closely related to vitamin D deficiency, abnormal umbilical blood flow, placental abnormalities, and FGR occurrence in pregnant women with HDP. In addition, TRAF6 and CTRP9 are also factors that affect the occurrence of FGR in pregnant women with HDP, and their combination can predict the occurrence of this complication.

ObjectiveTo investigate the expression of serum ELABELA(ELA), long non coding RNA lung adenocarcinoma transcript 1(MALAT1) in patients with gestational hypertension(HDCP), and their relationship with the severity of the disease and pregnancy outcomes.MethodsOne hundred and two patients with HDCP treated in our hospital from February 2021 to February 2023 were selected and divided into three subgroups based on the severity of their condition: gestational hypertension subgroup(34 cases), mild preeclampsia subgroup(35 cases), and severe preeclampsia subgroup(33 cases); Based on pregnancy outcomes, they were grouped by a good prognosis subgroup(66 cases) and a poor prognosis subgroup(36 cases), with 60 healthy pregnant women in the same period as the control group. Enzyme linked immunosorbent assay and qPCR were conducted to detect serum ELA and MALAT1 levels, respectively. The evaluation value of serum ELA and MALAT1 for adverse pregnancy outcomes in HDCP were analyzed by logistic regression model and receiver operating characteristic curve.ResultsThe serum ELA and MALAT1 levels in the HDCP group were lower than those in the control group(t/P=17.101/<0.001, 15.035/<0.001). The serum ELA and MALAT1 levels in the gestational hypertension subgroup, mild PE subgroup, and severe PE subgroup decreased sequentially(F/P=115.480/<0.001,40.421/<0.001). Compared with the good prognosis subgroup, the poor prognosis subgroup of HDCP patients had higher systolic blood pressure, lower serum MALAT1, and ELA(t/P=7.347/<0.001,8.898/<0.001,11.100/<0.001). Systolic blood pressure is a risk factor for adverse pregnancy outcomes in HDCP patients[OR(95%CI)=1.556(1.230-1.968)], while serum MALAT1 and ELA were protective factors [OR(95%CI)=0.680(0.548-0.843),0.754(0.617-0.920)].The area under the curve(95%CI) of the combined use of serum ELA and MALAT1 for prognostic evaluation of adverse pregnancy outcomes in HDCP was 0.912(0.881-0.940), which was superior to serum ELA and MALAT1 alone at 0.838(0.790-0.869) and 0.829(0.783-0.856)(Z/P=4.613/<0.001, 4.820/<0.001).ConclusionThe decreased levels of serum ELA and MALAT1 in patients with HDCP are related to the severity of the disease and adverse pregnancy outcomes. The combination of the two has high predictive value for clinical evaluation of adverse pregnancy outcomes in HDCP.

ObjectiveTo investigate the influencing factors and predictive value of the pan-immune inflammation value and chemokine expression profile in the recurrence after laparoscopic myomectomy.MethodsClinical data of 104 patients who underwent laparoscopic myomectomy at the Department of Obstetrics and Gynecology of Beijing Chaoyang Hospital, Capital Medical University and the Affiliated Hospital of Binzhou Medical University from January 2020 to February 2022 were retrospectively analyzed. According to the postoperative recurrence, the patients were divided into non-recurrence group(n=81) and recurrence group(n=23). The general clinical data, blood cell-related inflammatory indicators[erythrocyte sedimentation rate(ESR), pan-immune inflammation value(PIV), neutrophil-to-lymphocyte ratio(NLR), platelet-to-lymphocyte ratio(PLR), monocyte-to-lymphocyte ratio(MLR)], chemokine levels[CC chemokine ligand(CCL) 2, CCL8, CCL21], and sex hormone levels[follicle-stimulating hormone(FSH), luteinizing hormone(LH), estradiol(E2), testosterone(T)]were compared between the two groups. Logistic regression analysis was used to screen out the risk factors for recurrence after laparoscopic myomectomy. Receiver operating characteristic(ROC) curve and area under the curve(AUC) were used to evaluate the predictive value of each risk factor independently and jointly for recurrence after laparoscopic myomectomy.ResultsThe proportion of patients with a family history of uterine fibroids, ESR, PIV, NLR, CCL8, CCL21, FSH, LH, and E2levels were higher in the recurrence group than in the non-recurrence group(χ2/t/P=6.124/0.013, 3.602/<0.001, 4.278/<0.001, 3.905/<0.001, 4.454/<0.001, 3.841/<0.001, 4.123/<0.001, 3.351/0.001, 4.285/<0.001). Spearman correlation analysis and Logistic regression analysis showed that higher PIV, NLR, CCL8, CCL21, and E2levels were significant risk factors for recurrence after laparoscopic myomectomy[OR(95%CI)=1.026(1.006-1.046), 4.978(1.018-7.776), 1.231(1.058-1.432), 1.066(1.016-1.118), 1.032(1.004-1.060)]. ROC analysis showed that the AUCs of PIV, NLR, CCL8, CCL21 alone and the combination of the factors for predicting postoperative recurrence of uterine fibroids were 0.762, 0.703, 0.799, 0.739, and 0.966, respectively. The combined prediction of the five factors was better than that of each factor alone(Z=3.876, 4.145, 3.722, 3.956, allP<0.05).ConclusionPostoperative inflammatory indicators and chemokine levels can be combined with sex hormones to predict the risk of recurrence in patients after laparoscopic myomectomy. For such patients, close monitoring of inflammatory response levels and sex hormone changes after surgery is of certain clinical significance for preventing disease recurrence.